CR20130139A - DERIVATIVES OF 4- (5-CIANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119 - Google Patents

DERIVATIVES OF 4- (5-CIANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119

Info

Publication number
CR20130139A
CR20130139A CR20130139A CR20130139A CR20130139A CR 20130139 A CR20130139 A CR 20130139A CR 20130139 A CR20130139 A CR 20130139A CR 20130139 A CR20130139 A CR 20130139A CR 20130139 A CR20130139 A CR 20130139A
Authority
CR
Costa Rica
Prior art keywords
pirazol
ciano
gpr
modulators
piperidine
Prior art date
Application number
CR20130139A
Other languages
Spanish (es)
Inventor
Vincent Mascitti
Kim Francis Mcclure
Michael John Munchhof
Ralph Pelton Robinson Jr
Original Assignee
Kimberly Clark Co
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130139(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kimberly Clark Co, Pfizer filed Critical Kimberly Clark Co
Publication of CR20130139A publication Critical patent/CR20130139A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen compuestos que modulan la actividad del receptor GPR119 acoplado a la proteína G y sus usos para el tratamiento de enfermedades relacionadas con la modulación del receptor GPR119 acoplado a la proteína G en animales.Compounds that modulate the activity of the G-protein-coupled receptor GPR119 and their uses for the treatment of diseases related to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.

CR20130139A 2010-11-23 2013-03-22 DERIVATIVES OF 4- (5-CIANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119 CR20130139A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41644110P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
CR20130139A true CR20130139A (en) 2013-06-28

Family

ID=45418722

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130139A CR20130139A (en) 2010-11-23 2013-03-22 DERIVATIVES OF 4- (5-CIANO-PIRAZOL-1-IL) -PIPERIDINE AS MODULATORS OF GPR 119

Country Status (26)

Country Link
EP (1) EP2643310A1 (en)
JP (1) JP2013543885A (en)
KR (1) KR20130083915A (en)
CN (1) CN103298801A (en)
AP (1) AP2013006809A0 (en)
AR (1) AR088121A1 (en)
AU (1) AU2011333427A1 (en)
BR (1) BR112013011865A2 (en)
CA (1) CA2814231A1 (en)
CL (1) CL2013001054A1 (en)
CO (1) CO6801716A2 (en)
CR (1) CR20130139A (en)
CU (1) CU20130059A7 (en)
DO (1) DOP2013000102A (en)
EA (1) EA201370118A1 (en)
EC (1) ECSP13012630A (en)
GT (1) GT201300135A (en)
MA (1) MA34805B1 (en)
MX (1) MX2013004083A (en)
NI (1) NI201300044A (en)
PE (1) PE20140409A1 (en)
SG (1) SG189830A1 (en)
TW (1) TWI433843B (en)
UY (1) UY33742A (en)
WO (1) WO2012069948A1 (en)
ZA (1) ZA201302362B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6463631B2 (en) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Novel compounds as modulators of GPR-119
CN104780915A (en) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2017119628A (en) * 2014-05-09 2017-07-06 日産化学工業株式会社 Substituted azole compound and therapeutic agent for diabetes
CN104892517A (en) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 Hydrazine compound, method for preparing same and application of hydrazine compound
CN104610151A (en) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof
CN104592120A (en) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof
EP3416959B1 (en) 2016-02-18 2021-05-12 Syngenta Participations AG Pesticidally active pyrazole derivatives
CN106631992B (en) * 2017-01-05 2019-01-18 桑迪亚医药技术（上海）有限责任公司 A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185544B1 (en) * 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
TW201002705A (en) * 2008-03-31 2010-01-16 Metabolex Inc Oxymethylene aryl compounds and uses thereof
NZ596467A (en) * 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators

Also Published As

Publication number Publication date
MA34805B1 (en) 2014-01-02
NI201300044A (en) 2013-08-01
CA2814231A1 (en) 2012-05-31
SG189830A1 (en) 2013-06-28
PE20140409A1 (en) 2014-03-23
UY33742A (en) 2012-06-29
AU2011333427A1 (en) 2013-04-11
EP2643310A1 (en) 2013-10-02
DOP2013000102A (en) 2013-07-15
KR20130083915A (en) 2013-07-23
CU20130059A7 (en) 2013-06-28
GT201300135A (en) 2015-02-19
MX2013004083A (en) 2013-06-13
WO2012069948A1 (en) 2012-05-31
TWI433843B (en) 2014-04-11
AP2013006809A0 (en) 2013-04-30
CO6801716A2 (en) 2013-11-29
BR112013011865A2 (en) 2016-08-23
AR088121A1 (en) 2014-05-14
TW201300373A (en) 2013-01-01
EA201370118A1 (en) 2013-12-30
CN103298801A (en) 2013-09-11
ZA201302362B (en) 2014-06-25
CL2013001054A1 (en) 2013-09-27
JP2013543885A (en) 2013-12-09
ECSP13012630A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
CR20110623A (en) GPR MODULATORS 119
NI201300044A (en) DERIVATIVES OF 4 - (5 - CYANE - PIRAZOLE - 1 - IL) - PIPERIDINE AS MODULATORS OF GPR 119
SV2016005192A (en) COMPOSITIONS AND METHODS TO MODULATE X-FARNESOID RECEPTORS
ECSP14021251A (en) DIACILGLICEROL ACILTRANSFERASE 2 INHIBITORS
CL2015002567A1 (en) Compounds and their uses to modulate hemoglobin
CR10949A (en) TRICYCLE COMPOUNDS, COMPOSITIONS AND PROCEDURES
CO7160047A2 (en) Compounds and compositions that modulate epidermal growth factor receptor activity (egfr)
ECSP14017269A (en) COMPOUNDS TO TREAT SPINAL MUSCULAR ATROPHY
UY33815A (en) COMPOSITIONS AND METHODS TO MODULATE THE FXR
CO6771417A2 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
UY33409A (en) NON-COMPETITIVE MODULATORS OF NICOTINIC RECEPTORS
ECSP11010795A (en) FENANTRENONE COMPOUNDS, COMPOSITIONS AND METHODS
CU20080116A7 (en) 3-AMINOCICLOPENTANOCARBOXAMIDS AS MUDULATORS OF CHEMIOKIN RECEPTORS
UA101110C2 (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr119 modulators
DOP2009000191A (en) TRICYCLE COMPOUNDS AND THEIR USE AS GLUCOCORTICOID RECEPTOR MODULATORS